Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation PHARMACOGENOMICS JOURNAL Leventhal, A. M., David, S. P., Brightman, M., Strong, D., McGeary, J. E., Brown, R. A., Lloyd-Richardson, E. E., Munafo, M., Uhl, G. R., Niaura, R. 2012; 12 (1): 86-92

Abstract

Smokers (=10 cigarettes per day, N=331) of European ancestry taking part in a double-blind placebo-controlled randomized trial of 12 weeks of treatment with bupropion along with counseling for smoking cessation were genotyped for a variable number of tandem repeats polymorphism in exon III of the dopamine D4 receptor gene. Generalized estimating equations predicting point-prevalence abstinence at end of treatment and 2, 6 and 12 months after the end of treatment indicated that bupropion (vs placebo) predicted increased odds of abstinence. The main effect of Genotype was not significant. A Genotype × Treatment interaction (P=0.005) showed that bupropion predicted increased odds of abstinence in long-allele carriers (odds ratios (OR)=1.31, P<0.0001), whereas bupropion was not associated with abstinence among short-allele homozygotes (OR=1.06, P=0.23). The Genotype × Treatment interaction remained when controlling for demographic and clinical covariates (P=0.01) and in analyses predicting continuous abstinence (P's=0.054). Bupropion may be more efficacious for smokers who carry the long allele, which is relevant to personalized pharmacogenetic treatment approaches.

View details for DOI 10.1038/tpj.2010.64

View details for Web of Science ID 000299719200010

View details for PubMedID 20661272

View details for PubMedCentralID PMC2981689